AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US
Filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic COVID-19 with long-acting antibody combination (non-vaccine) Potential to provide protection for those not expected to mount an adequate immune response following vaccinationAstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic COVID-19. If granted, AZD7442 would be the first LAAB to receive an EUA for COVID-19 prevention. It